Home  |  Contact

UniProtKB/Swiss-Prot O60880: Variant p.Phe87Ser

SH2 domain-containing protein 1A
Gene: SH2D1A
Variant information

Variant position:  87
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Phenylalanine (F) to Serine (S) at position 87 (F87S, p.Phe87Ser).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (F) to small size and polar (S)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In XLP1; reduced protein stability and reduced affinity for SLAMF1 and FYN.
Any additional useful information about the variant.



Sequence information

Variant position:  87
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  128
The length of the canonical sequence.

Location on the sequence:   ETAPGVHKRYFRKIKNLISA  F QKPDQGIVIPLQYPVEKKSS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSS

Rhesus macaque                ETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSS

Mouse                         ETAPGVHKRFFRKVKNLISAFQKPDQGIVTPLQYPVEK-SS

Rat                           ETAPGVHKRFFRKVKNLISAFQKPDQGIVTPLQYPVEK-SS

Pig                           DTAPGVHKRFFRKIKNLISAFQKPDQGIVIPLQYPVEKKSS

Bovine                        ETAPGVHKRFFRKIKNLISAFQKPDQGIVIPLQYPVEKKPS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 128 SH2 domain-containing protein 1A
Domain 6 – 104 SH2
Region 67 – 92 Interaction with FYN SH3 domain
Modified residue 89 – 89 N6-acetyllysine
Alternative sequence 40 – 128 VYCLCVLYHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSSARSTQGTTGIREDPDVCLKAP -> ITVTFIHTECPRQKQVLGVLSISEARSRHCNTSAVSS. In isoform E.
Alternative sequence 47 – 128 YHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSSARSTQGTTGIREDPDVCLKAP -> QHLGYIKDISGK. In isoform C.
Alternative sequence 47 – 128 YHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSSARSTQGTTGIREDPDVCLKAP -> ISEARSRHCNTSAVSS. In isoform F.
Alternative sequence 68 – 128 TAPGVHKRYFRKIKNLISAFQKPDQGIVIPLQYPVEKKSSARSTQGTTGIREDPDVCLKAP -> HFRSQIKA. In isoform B.
Mutagenesis 78 – 78 R -> E. Disrupts interaction with FYN.
Helix 80 – 87


Literature citations

Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
Sumegi J.; Huang D.; Lanyi A.; Davis J.D.; Seemayer T.A.; Maeda A.; Klein G.; Seri M.; Wakiguchi H.; Purtilo D.T.; Gross T.G.;
Blood 96:3118-3125(2000)
Cited for: VARIANTS XLP1 CYS-7; ARG-28; PRO-31; TRP-42; ILE-53; CYS-54; SER-87; PRO-99 AND GLY-102;

Disease-causing SAP mutants are defective in ligand binding and protein folding.
Li C.; Iosef C.; Jia C.Y.H.; Gkourasas T.; Han V.K.M.; Li S.-C.;
Biochemistry 42:14885-14892(2003)
Cited for: CHARACTERIZATION OF VARIANTS XLP1 PRO-31; CYS-54; LEU-55 AND SER-87;

Missense mutations in SH2D1A identified in patients with X-linked lymphoproliferative disease differentially affect the expression and function of SAP.
Hare N.J.; Ma C.S.; Alvaro F.; Nichols K.E.; Tangye S.G.;
Int. Immunol. 18:1055-1065(2006)
Cited for: VARIANTS XLP1 CYS-54; THR-84 AND SER-87; CHARACTERIZATION OF VARIANTS XLP1 CYS-54; THR-84 AND SER-87;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.